Our findings also show that administering a CaSR NAM [22,24] nearly totally or considerably hinders the oversecretion of such neuroinflammatory agents, demonstrating further anti-AD beneficial effects of calcilytics to be added to the several ones previously reported [15,20,21,35,36,54]. The gene discussed is CASR; the disease is Alzheimer disease.